

AHCCCS Pharmacy and Therapeutics Committee

Meeting Minutes

May 21, 2025

Members Present:

Aida Amado
Aimee Schwartz
Alana Podwika
Sandy Brownstein
Crissy McGann
Kelly Flannigan
Maria Cole
Raul Romero
Steven Borodkin
Yvonne Johnson

Members Absent:

Sophie Dietrich
Jonathan Enchinton
Andrew Thatcher
Otto Uhrig

AHCCCS Staff:

Suzi Berman
Lauren Prole
Robin Davis
Theresa Costales
Susan Kennard

Magellan Medicaid Admin:

Umang Patel
Hind Douiki
Nina Bandali

WELCOME AND INTRODUCTIONS: SUZI BERMAN, RPH, AHCCCS PHARMACY DIRECTOR

1. Suzi Berman called the meeting to order at 12:02 and welcomed committee members, staff and public attendees.
2. The meeting minutes from the January 15, 2025 meeting were reviewed.
 - a. Motion to accept:
 - i. Aida Amado
 - ii. Alana Podwika

LEGISLATIVE REPORT UPDATE: SUZI BERMAN, RPH, AHCCCS PHARMACY DIRECTOR

HB2903 required AHCCCS to submit report to the Governor's Office, the President of the Senate, the Speaker of the House of Representatives, the chairperson of the Health and Human Services Committee, or its successor, in the senate and the chairperson of the Health Committee, or its successor, in the House of Representatives, director of the Joint Legislative Budget Committee and the director of the Governor's Office of Strategic Planning and Budgeting and shall provide a copy of this report to the Secretary of State.

SUPPLEMENTAL REBATE CLASS REVIEWS: UMANG PATEL, PHARMD, PRIME THERAPEUTICS

Supplemental Rebate Drug Class Review: Clinical review by Umang Patel, PharmD, Magellan/Prime Therapeutics

1. **Analgesics, Long-Acting Narcotic**
 - a. Public Testimony: None
2. **Antibiotics, Inhaled**
 - a. Public Testimony – Oral:
 - i. Michelle Ratkiewicz
3. **Antimigraine Agents, Other**
 - a. Public Testimony – Written:
 - i. Mandeep Sohal
4. **Antipsychotics, Atypical Long-Acting Injectable**
 - a. Public Testimony – Oral:
 - i. Stefan Luft
 - ii. Mandeep Sohal
 - b. Public Testimony – Written:
 - i. Carrie Bowman
 - ii. Josie Cooper
 - iii. Casey Hollingsworth
 - iv. Tammy Hostetler
 - v. Miguel Tosado

5. Antipsychotics, Oral Atypical (2nd Gen Only)

- a. Public Testimony – Oral:
 - i. Amy Filleman
 - ii. Scott Gilman
 - iii. Chung Trinh
- b. Public Testimony – Written:
 - i. David Delawder
 - ii. Christine Gonzalez
 - iii. Cindy Komar
 - iv. Kristen Pyland
 - v. Kristina Sabetta
 - vi. Tabitha Salzer

6. Colony Stimulating Factors

- a. Public Testimony: None

7. COPD Agents

- a. Public Testimony: None

8. Cytokine and CAM Antagonists

- a. Public Testimony – Oral:
 - i. Amy Hale
- b. Public Testimony – Written:
 - i. Mandeep Sohal

9. Glucagon Agents

- a. Public Testimony – Written:
 - i. Rachel Shubitz

10. Glucocorticoids, Inhaled

- a. Public Testimony – Oral:
 - i. Christine Dube

11. Growth Hormone

- a. Public Testimony – Written:
 - i. Joel Hahnke
 - ii. Chirag Kapadia

12. Hepatitis C Agents

- a. Public Testimony: None

13. Hypoglycemics (Insulin and Related Agents)

- a. Public Testimony: None

14. Hypoglycemics, Incretin Mimetics/Enhancers

- a. Public Testimony – Oral:
 - i. Justen Caleca
- b. Public Testimony – Written:
 - i. Lory Baraz
 - ii. Edgardo Laurel

15. Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma)

- a. Public Testimony – Oral:
 - i. Becca Colamarino
 - ii. Carla McSpadden
 - iii. Krystle Thai
- b. Public Testimony – Written:
 - i. Christine Dube

16. Movement Disorders

- a. Public Testimony – Oral:
 - i. Ray Kong
- b. Public Testimony – Written:
 - i. Mandeep Sohal

17. Multiple Sclerosis Agents

- a. Public Testimony – Oral:
 - i. Shirley Quach
 - ii. Payal Tejani
- b. Public Testimony – Written:
 - i. Stephanie Niemi-Olson
 - ii. Michael Robers
 - iii. Naveed Vehra

18. Opioid Dependence Treatments

- a. Public Testimony – Oral:
 - i. Megan Penner

19. Pancreatic Enzymes

- a. Public Testimony: None

20. Stimulants and Related Agents

- a. Public Testimony – Oral:
 - i. Patrick Harvey
- b. Public Testimony – Written:
 - i. Kristina Sabetta
 - ii. Joseph Werther

New Drug Reviews UMANG PATEL , PHARM D, MAGELLAN

1. Alyftrek

2. Crenesity

- a. Public Testimony – Written:
 - i. Ray Kong

3. Tryngolza

4. Tryvio

Executive Session – Closed to the Public

Public Therapeutic Class Votes:

1. Analgesics, Long-Acting Narcotic

- a. Preferred Products
 - i. Butrans (Brand is preferred over generic)
 - ii. fentanyl transdermal (not including the 37.5mg, 62.5mg & 87.5 strengths)
 - iii. methadone tablet, methadone sol tablet, methadone solution, methadone concentration (new)
 - iv. morphine ER tablet
 - v. tramadol ER (generic Ultram ER)
- b. Moving to Non-Preferred
 - i. Manufacturers no longer participating in MDRP
 - 1. Nucynta ER
 - 2. Xtampza ER

2. Antibiotics, Inhaled

- a. Preferred Products
 - i. Bethkis
 - ii. Kitabis Pak
- b. Grandfathering applies

3. Antimigraine Agents, Other

- a. Preferred Products
 - i. Aimovig
 - ii. dihydroergotamine mesylate nasal (AG)
 - iii. Emgality Syringe 120mg
 - iv. Emgality Pen
 - v. Migranal
 - vi. Ubrelvy
- b. Moving to Non-Preferred
 - i. Manufacturer no longer participating in MRDP
 - 1. Ergotamine Tartrate/Caffeine

4. Antipsychotics, Atypical Long-Acting Injectable

- a. Preferred Products
 - i. Abilify Asimtufii
 - ii. Abilify Maintena
 - iii. Aristada
 - iv. Aristada Initio
 - v. Invega Hafyera

- vi. Invega Sustenna
- vii. Invega Trinza
- viii. Risperdal Consta
- b. Moving to Non-Preferred
 - i. Olanzapine IM
 - ii. Perseris - Manufacturer is discontinuing product
 - iii. Zyprexa IM

5. Antipsychotics, Oral Atypical (2nd Gen Only)

- a. Preferred Products
 - i. aripiprazole tablet
 - ii. clozapine ODT
 - iii. clozapine tablet
 - iv. lurasidone
 - v. olanzapine ODT, olanzapine tablet
 - vi. quetiapine tablet
 - vii. risperdone ODT, risperidone solution, risperidone tablet
 - viii. ziprasidone capsule; ziprasidone capsule AG

6. Colony Stimulating Factors

- a. Preferred Products
 - i. Fulphila (new)
 - ii. Fylnetra
 - iii. Nivestym syringe, Nivestym vial
 - iv. Releuko syringe (new)
- b. Moving to Non-Preferred
 - i. Neupogen syringe, Neupogen vial
 - ii. Nyvepria
 - iii. Udenyca autoinjector
 - iv. Ziextenzo

7. COPD Agents

- a. Preferred Products
 - i. Antimuscarinics - Short-Acting
 - 1. Atrovent HFA
 - 2. ipratropium nebulizer
 - ii. Antimuscarinics - Long-Acting
 - 1. Tiotropium (Generic Spiriva Handihaler) (new)
 - 2. Spiriva Respimat
 - 3. Tudorza Pressair
 - iii. Beta Agonist/Antimuscarinic Combination - Short-Acting
 - 1. ipratropium/albuterol nebulizer
 - 2. Combivent Respimat
 - iv. Beta Agonist/Antimuscarinic Combination - Long-Acting

1. Anoro Ellipta
2. Stiolto Respimat
- b. Moving to Non-Preferred
 - i. Spiriva Handihaler

8. Cytokine and CAM Antagonists

- a. Preferred Products
 - i. Enbrel Kit, Enbrel Syringe, Enbrel Pen, Enbrel Mini Cartridge, Enbrel Vial
 - ii. Hadlima (Adalimumab-bwwd), Adalimumab-fkjp (Biocon)
 - iii. Infliximab (Unbranded by J&J)
 - iv. Orencia Clickject, Orencia Syringe
 - v. Otezla
 - vi. Tyenne Autoinjector, Tyenne Syringe, Tyenne Vial (Biosimilar for Actemra) (new)
 - vii. Xeljanz
 - viii. Xeljanz XR
 - ix. Yesintek (Biosimilar for Stelara) (new)
- b. Moving to Non-Preferred
 - i. Adalimumab-adbm (Manufactured by Boehringer)
 - ii. Simlandi

9. Glucagon Agents

- a. Preferred Products
 - i. Baqsimi (Nasal)(new)
 - ii. glucagon injection
 - iii. glucagon emergency kit (by Amphastar)
 - iv. Proglycem Suspension
 - v. Zegalogue Autoinjector, Zegalogue Syringe (new)
- b. Moving to Non-Preferred
 - i. Gvoke Pen, Gvoke Syringe, Gvoke Vial

10. Glucocorticoids, Inhaled

- a. Preferred Products
 - i. Single Agent Products
 1. Arnuity Ellipta
 2. Asmanex
 3. budesonide 1 mg respules
 4. budesonide 0.25 & 0.5 mg respules
 5. Flovent Diskus
 6. Flovent HFA
 7. fluticasone diskus AG
 8. fluticasone HFA AG
 9. Pulmicort Flexhaler

- 10. QVAR Redihaler
- ii. Combination Products
 - 1. Airduo Resplick
 - 2. Advair HFA
 - 3. budesonide/formoterol (AG) (new)
 - 4. Dulera
 - 5. Fluticasone/Salmeterol (Advair) (AG) (Inhalation) (new)
 - 6. Fluticasone/Salmeterol (Advair) (Inhalation) (new)
- b. Moving to Non-Preferred
 - i. Advair Diskus
 - ii. Symbicort

11. Growth Hormone

- a. Preferred Products
 - i. Genotropin Cartridge (new)
 - ii. Genotropin Disp Syringe
 - iii. Norditropin Pen

12. Hepatitis C Agents

- a. Preferred Products
 - i. Mavyret
 - ii. sofosbuvir/velpatasvir (AG) - (Generic Epclusa)

13. Hypoglycemics (Insulin and Related Agents)

- a. Preferred Products
 - i. Rapid-Acting Insulins
 - 1. insulin aspart cartridge (AG)
 - 2. insulin aspart pen (AG)
 - 3. insulin aspart vial (AG)
 - 4. insulin lispro junior kwikpen (AG)
 - 5. insulin lispro pen (AG)
 - 6. insulin lispro vial (AG)
 - ii. Regular Insulins
 - 1. Humulin 500 Pens, Humulin 500 Vials
 - 2. Novolin Vial OTC
 - iii. Long-Acting Insulins
 - 1. insulin degludec pen 100U/mL
 - 2. insulin degludec pen 200U/mL
 - 3. insulin degludec vial
 - 4. Lantus Vial
 - 5. Lantus Solostar Pen
 - iv. Rapid/Intermediate-Acting Combination Insulins
 - 1. insulin aspart/insulin aspart protamine vial (AG)

2. insulin aspart/insulin aspart protamine insulin pen (AG)
3. insulin lispro protamine mix kwikpen (AG)
- v. Regular/Intermediate-Acting Combination Insulins
 1. Humulin Pen 70/30 OTC, Humulin 70/30 Vial OTC
- b. Moving to Non-Preferred
 - i. Humalog Cartridge
 - ii. Humalog Mix Vial
 - iii. Novolin 70/30 Vial OTC

14. Hypoglycemics, Incretin Mimetics/Enhancers

- a. Preferred Products
 - i. Dipeptidyl Peptidase-4 Enzyme Inhibitors (DPP-4s)
 1. alogliptin (AG)
 2. alogliptin/metformin (AG)
 3. alogliptin/pioglitazone (AG)
 4. Janumet
 5. Janumet XR
 6. Januvia
 7. Jentadueto
 8. Jentadueto XR
 9. Kombiglyze XR
 10. Tradjenta
 11. Trijardy XR
 - ii. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s)
 1. Bydureon Pens (Discontinued by manufacturer as supplies last)
 2. Byetta Pens (Discontinued by manufacturer as supplies last)
 3. Exenatide Pens (Byetta Generic) (new)
 4. Trulicity
 5. Victoza
 6. Liraglutide (AG for Victoza) (new)
 - iii. Amylin Analogues
 1. Symlin Pens
- b. Moving to Non-Preferred
 - i. Kazano
 - ii. Oseni (discontinued)

15. Immunologics (Immunomodulators, Atopic Dermatitis and Immunomodulators, Asthma)

- a. Preferred Products
 - i. Adbry Autoinjector
 - ii. Adbry Syringe

- iii. Elidel
- iv. Eucrisa
- v. Fasenra Pen (new)
- vi. Fasenra Syringe (new)
- vii. Opzelura
- viii. pimecrolimus, pimecrolimus (AG)
- ix. tacrolimus, tacrolimus (AG)
- x. Vtama Cream 1% (new)
- xi. Xolair Syringe (new)
- xii. Xolair Vial (new)
- xiii. Zoryve 0.15% Cream (new)
- b. Moving to Non-Preferred
 - i. Cinqair
 - ii. Nucala Auto-Injector
 - iii. Nucala Syringe
 - iv. Nucala Vial
 - v. Tezspire Pen
 - vi. Tezspire Syringe

16. Movement Disorders

- a. Preferred Products
 - i. Austedo (ORAL)
 - ii. Austedo XR (ORAL)
 - iii. Austedo XR Titration Kit (ORAL)
 - iv. Ingrezza (ORAL)
 - v. Ingrezza Initiation Pack (ORAL)
 - vi. Ingrezza Sprinkle (ORAL)

17. Multiple Sclerosis Agents

- a. Preferred Products
 - i. Avonex (INTRAMUSC.)
 - ii. Avonex Pen (INTRAMUSC.)
 - iii. Briumvi (INTRAV.) (new)
 - iv. Copaxone 20 MG/ML (SUBCUTANE.)
 - v. Copaxone 40 MG/ML (SUBCUTANE.)
 - vi. Dalfampridine ER (ORAL)
 - vii. Dimethyl Fumarate DR (ORAL)
 - viii. Fingolimod (ORAL)
 - ix. Kesimpta (SUBCUTANE.)
 - x. Ocrevus (INTRAV.)
 - xi. Ocrevus Vial (SUBCUTANE.)
 - xii. Rebif (SUBCUTANE.)
 - xiii. Rebif Rebidoso Pen Injector (SUBCUTANE.)

- xiv. Teriflunomide Tablet (ORAL)
- xv. Tysabri(INTRAVEN.)
- b. Grandfathering applies

18. Opioid Dependence Treatments

- a. Preferred Products
 - i. Buprenorphine/Naloxone Products
 - 1. buprenorphine/naloxone sublingual tablet
 - 2. Suboxone Film (Brand is preferred over generic)
 - ii. Buprenorphine Products
 - 1. Brixadi – with PA
 - 2. buprenorphine sublingual tablet –PA required unless member is pregnant
 - 3. Sublocade subcutaneous – with PA
 - iii. Alpha Agonist Products
 - 1. clonidine tablet
 - iv. Naloxone Products
 - 1. Kloxxado Spray
 - 2. naloxone syringe, naloxone vials
 - 3. Naloxone Nasal OTC
 - 4. Narcan Nasal
 - 5. Narcan Nasal OTC
 - 6. Rextovy Nasal Spray
 - v. Naltrexone Products
 - 1. naltrexone tablets
 - 2. Vivitrol

19. Pancreatic Enzymes

- a. Preferred Products
 - i. Creon
 - ii. Zenpep

20. Stimulants and Related Agents

- a. Preferred Products
 - i. amphetamine salt combination
 - ii. amphetamine salt combination ER
 - iii. amphetamine salt combination ER (AG)
 - iv. armodafinil (AG) (new)
 - v. atomoxetine, atomoxetine (AG)
 - vi. clonidine ER
 - vii. Daytrana
 - viii. dexamethylphenidate,
 - ix. dexamethylphenidate (AG)

- x. dexamethylphenidate ER
- xi. dextroamphetamine tablet
- xii. guanfacine ER
- xiii. Methylin Solution (Brand is Preferred over generic)
- xiv. methylphenidate
- xv. methylphenidate CD, methylphenidate CD (AG)
- xvi. Methylphenidate ER (Concerta)
- xvii. modafinil (new)
- xviii. Ritalin LA
- xix. Vyvanse Capsule (Brand is Preferred over generic)
- b. Moving to Non-Preferred
 - i. armodafinil
 - ii. Concerta
 - iii. Nuvigil
 - iv. Provigil
 - v. Sunosi
 - vi. Wakix
- c. Grandfathering does not apply to his class

21. The committee voted on all above Supplemental rebate class recommendations

- a. All present committee members voted in favor of the recommendations.
- b. No committee members voted against the recommendations.
- c. No committee members abstained.

New Drug Recommendations

- 1. Alyftrek**
- 2. Crenessity**
- 3. Tryngolza**
- 4. Tryvio**

- a. The recommendation for the New Drugs is Non-Preferred
- b. The committee voted on the above recommendations.
 - i. All present committee members voted in favor of the recommendations.
 - ii. No committee members voted against the recommendations.
 - iii. No committee members abstained.

AHCCCS Pharmacy and Therapeutics Committee
Meeting Minutes
May 21, 2025

BRAND NAME PRODUCT	GENERIC NAME	PREFERRED BIOSIMILAR LABEL NAME	PREFERRED BIOSIMILAR CHEMICAL NAME	PREFERRED PRODUCTS MOVING TO NON- PREFERRED STATUS	PREFERRED BIOSIMILAR MANUFACTURER
EYLEA	AFLIBERCEPT	PAVBLU	AFLIBERCEPT-AYYH	NEW ADDITION	AMGEN
HUMIRA	ADALIMUMAB	UNBRANDED VERSION	ADALIMUMAB-FJKP	SIMLANDI	BIOCON BIOLOGICS
		HADLIMA	ADALIMUMAB- BWWD	ADALIMUMAB-ABDM	ORGANON
AVASTIN	BEVACIZUMAB	MVASI	BEVACIZUMAB-AWWB	NO CHANGES	AMGEN
		ZIRABEV	BEVACIZUMAB-BVZR		PFIZER
SOLIRIS	ECULIZUMAB	EPYSQLI	ECULIZUMAB-AAGH	NEW ADDITION	TEVA
NEUPOGEN	FILGRASTIM	RELEUKO	FILGRASTIM-AYOW	NEUPOGEN	AMNEAL
		NIVESTYM	FILGRASTIM-AAFI		PFIZER
NEULASTA	PEGFILGRASTIM	FULPHILA	PEGFILGRASTIM-JMDB	UNDENYCA	MYLAN
		FYLNETRA	PEGFILGRASTIM-PBBK	NYVEPRIA	AMNEAL
				ZIEXTENZO	
LUCENTIS	RANIBIZUMAB	CIMERLI	RANIBIZUMAB-EQRN	NEW ADDITION	SANDOZ
RITUXAN	RITUXIMAB	RIABNI	RITUXIMAB-ARRX	TRUXIMA	AMGEN
		RUXIENCE	RITUXIMAB-PVVR		PFIZER
ACTEMRA	TOCILIZUMAB	TYENNE	TOCILIZUMAB-AAZG	NEW ADDITION	FRESENIUS
HERCEPTIN	TRASTUZUMAB	OGIVRI	TRASTUZUMAB-DKST	KANJINTI, HERZUMA TRAZIMERA	MYLAN-BIOCON BIOLOGICS
STELARA	USTEKINUMAB	YESINTEK	USTEKINUMAB-KFCE	NEW ADDITION	BIOCON BIOLOGICS

ADJOURNMENT:

The meeting adjourned at 4:54 PM

Minutes recorded by Robin Davis

Suzanne Berman RPH

Suzi Berman, RPh
Director of Pharmacy Services

Date October 22, 2025

FUTURE MEETING DATES: October 22, 2025, January 13, 2026